Listed

Agios Pharmaceuticals, Inc.

AGIONasdaqCIK 1439222HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$44.7m, Q2 FY2026
Operating income−$110.6m, Q2 FY2026
Net income−$100.7m, Q2 FY2026
Agios Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m7.4Revenue, Q3 FY2023, three months to 2023-09-30$7.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure7.1Revenue, Q4 FY2023, three months to 2023-12-31$7.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure8.2Revenue, Q1 FY2024, three months to 2024-03-31$8.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure8.6Revenue, Q2 FY2024, three months to 2024-06-30$8.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-07-31, accession 0001439222-25-000089.Report this figure9.0Revenue, Q3 FY2024, three months to 2024-09-30$9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure10.7Revenue, Q4 FY2024, three months to 2024-12-31$10.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure8.7Revenue, Q1 FY2025, three months to 2025-03-31$8.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure12.5Revenue, Q2 FY2025, three months to 2025-06-30$12.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure12.9Revenue, Q3 FY2025, three months to 2025-09-30$12.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure20.0Revenue, Q4 FY2025, three months to 2025-12-31$20.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure20.7Revenue, Q1 FY2026, three months to 2026-03-31$20.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure44.7Revenue, Q2 FY2026, three months to 2026-06-30$44.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Cost of revenue$m0.6Cost of revenue, Q3 FY2023, three months to 2023-09-30$633.0k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure0.6Cost of revenue, Q4 FY2023, three months to 2023-12-31$586.0k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure0.6Cost of revenue, Q1 FY2024, three months to 2024-03-31$627.0k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure1.5Cost of revenue, Q2 FY2024, three months to 2024-06-30$1.5m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-07-31, accession 0001439222-25-000089.Report this figure0.8Cost of revenue, Q3 FY2024, three months to 2024-09-30$783.0k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure1.3Cost of revenue, Q4 FY2024, three months to 2024-12-31$1.3m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure1.1Cost of revenue, Q1 FY2025, three months to 2025-03-31$1.1m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure1.7Cost of revenue, Q2 FY2025, three months to 2025-06-30$1.7m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure1.7Cost of revenue, Q3 FY2025, three months to 2025-09-30$1.7m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure1.9Cost of revenue, Q4 FY2025, three months to 2025-12-31$1.9m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure1.3Cost of revenue, Q1 FY2026, three months to 2026-03-31$1.3m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure3.0Cost of revenue, Q2 FY2026, three months to 2026-06-30$3.0m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Research and development$m81.8Research and development, Q3 FY2023, three months to 2023-09-30$81.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure77.5Research and development, Q4 FY2023, three months to 2023-12-31$77.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure68.6Research and development, Q1 FY2024, three months to 2024-03-31$68.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure77.4Research and development, Q2 FY2024, three months to 2024-06-30$77.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-07-31, accession 0001439222-25-000089.Report this figure72.5Research and development, Q3 FY2024, three months to 2024-09-30$72.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure82.8Research and development, Q4 FY2024, three months to 2024-12-31$82.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure72.7Research and development, Q1 FY2025, three months to 2025-03-31$72.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure91.9Research and development, Q2 FY2025, three months to 2025-06-30$91.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure86.8Research and development, Q3 FY2025, three months to 2025-09-30$86.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure88.1Research and development, Q4 FY2025, three months to 2025-12-31$88.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure81.1Research and development, Q1 FY2026, three months to 2026-03-31$81.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure101Research and development, Q2 FY2026, three months to 2026-06-30$100.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Selling, general and administrative$m25.8Selling, general and administrative, Q3 FY2023, three months to 2023-09-30$25.8m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure35.3Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$35.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure31.0Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$31.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure35.5Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$35.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-07-31, accession 0001439222-25-000089.Report this figure38.5Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$38.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure51.7Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$51.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure41.5Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$41.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure45.9Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$45.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure41.3Selling, general and administrative, Q3 FY2025, three months to 2025-09-30$41.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure51.6Selling, general and administrative, Q4 FY2025, three months to 2025-12-31$51.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure48.3Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$48.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure51.5Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$51.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Operating income$m(101)Operating income, Q3 FY2023, three months to 2023-09-30−$100.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure(106)Operating income, Q4 FY2023, three months to 2023-12-31−$106.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(92.1)Operating income, Q1 FY2024, three months to 2024-03-31−$92.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure(106)Operating income, Q2 FY2024, three months to 2024-06-30−$105.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-07-31, accession 0001439222-25-000089.Report this figure(103)Operating income, Q3 FY2024, three months to 2024-09-30−$102.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure(125)Operating income, Q4 FY2024, three months to 2024-12-31−$125.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(107)Operating income, Q1 FY2025, three months to 2025-03-31−$106.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(127)Operating income, Q2 FY2025, three months to 2025-06-30−$127.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure(117)Operating income, Q3 FY2025, three months to 2025-09-30−$116.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure(122)Operating income, Q4 FY2025, three months to 2025-12-31−$121.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(110)Operating income, Q1 FY2026, three months to 2026-03-31−$110.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(111)Operating income, Q2 FY2026, three months to 2026-06-30−$110.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported53.1Income tax, Q3 FY2024, three months to 2024-09-30$53.1m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure(8.9)Income tax, Q4 FY2024, three months to 2024-12-31−$8.9m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure(1.0)Income tax, Q4 FY2025, three months to 2025-12-31−$1.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Net income$m(91.3)Net income, Q3 FY2023, three months to 2023-09-30−$91.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure(95.9)Net income, Q4 FY2023, three months to 2023-12-31−$95.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(81.5)Net income, Q1 FY2024, three months to 2024-03-31−$81.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure(96.1)Net income, Q2 FY2024, three months to 2024-06-30−$96.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure948Net income, Q3 FY2024, three months to 2024-09-30$947.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure(96.5)Net income, Q4 FY2024, three months to 2024-12-31−$96.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(89.3)Net income, Q1 FY2025, three months to 2025-03-31−$89.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure(112)Net income, Q2 FY2025, three months to 2025-06-30−$112.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure(103)Net income, Q3 FY2025, three months to 2025-09-30−$103.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure(108)Net income, Q4 FY2025, three months to 2025-12-31−$108.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(99.1)Net income, Q1 FY2026, three months to 2026-03-31−$99.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure(101)Net income, Q2 FY2026, three months to 2026-06-30−$100.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Diluted EPS$ per share(1.64)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$1.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figurenot reported(1.45)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure(1.69)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$1.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-07-31, accession 0001439222-25-000089.Report this figure16.22Diluted EPS, Q3 FY2024, three months to 2024-09-30$16.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figurenot reported(1.55)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(1.93)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$1.93 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure(1.78)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.78 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figurenot reported(1.69)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(1.69)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Basic EPS$ per share(1.64)Basic EPS, Q3 FY2023, three months to 2023-09-30−$1.64 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figurenot reported(1.45)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure(1.69)Basic EPS, Q2 FY2024, three months to 2024-06-30−$1.69 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-07-31, accession 0001439222-25-000089.Report this figure16.65Basic EPS, Q3 FY2024, three months to 2024-09-30$16.65 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figurenot reported(1.55)Basic EPS, Q1 FY2025, three months to 2025-03-31−$1.55 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(1.93)Basic EPS, Q2 FY2025, three months to 2025-06-30−$1.93 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure(1.78)Basic EPS, Q3 FY2025, three months to 2025-09-30−$1.78 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figurenot reported(1.69)Basic EPS, Q1 FY2026, three months to 2026-03-31−$1.69 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(1.69)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.69 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure

Balance sheet

Cash and equivalents$99.6m, Q2 FY2026
Shareholders' equity$1.03bn, Q2 FY2026
Agios Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m64.3Cash and equivalents, Q3 FY2023, at 2023-09-30$64.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-02, accession 0001439222-23-000140.Report this figure88.2Cash and equivalents, FY2023, at 2023-12-31$88.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-13, accession 0001439222-25-000009.Report this figure119Cash and equivalents, Q1 FY2024, at 2024-03-31$118.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-02, accession 0001439222-24-000069.Report this figure84.5Cash and equivalents, Q2 FY2024, at 2024-06-30$84.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-01, accession 0001439222-24-000121.Report this figure254Cash and equivalents, Q3 FY2024, at 2024-09-30$253.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure76.2Cash and equivalents, FY2024, at 2024-12-31$76.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure79.0Cash and equivalents, Q1 FY2025, at 2025-03-31$79.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure80.9Cash and equivalents, Q2 FY2025, at 2025-06-30$80.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-07-31, accession 0001439222-25-000089.Report this figure92.7Cash and equivalents, Q3 FY2025, at 2025-09-30$92.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure89.1Cash and equivalents, FY2025, at 2025-12-31$89.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure114Cash and equivalents, Q1 FY2026, at 2026-03-31$113.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure99.6Cash and equivalents, Q2 FY2026, at 2026-06-30$99.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Current assets$m704Current assets, Q3 FY2023, at 2023-09-30$704.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-02, accession 0001439222-23-000140.Report this figure834Current assets, FY2023, at 2023-12-31$833.8m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-13, accession 0001439222-25-000009.Report this figure664Current assets, Q1 FY2024, at 2024-03-31$663.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-02, accession 0001439222-24-000069.Report this figure632Current assets, Q2 FY2024, at 2024-06-30$632.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-01, accession 0001439222-24-000121.Report this figure1,074Current assets, Q3 FY2024, at 2024-09-30$1.07bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure966Current assets, FY2024, at 2024-12-31$965.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure969Current assets, Q1 FY2025, at 2025-03-31$968.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure1,019Current assets, Q2 FY2025, at 2025-06-30$1.02bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-07-31, accession 0001439222-25-000089.Report this figure1,033Current assets, Q3 FY2025, at 2025-09-30$1.03bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure942Current assets, FY2025, at 2025-12-31$942.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure835Current assets, Q1 FY2026, at 2026-03-31$834.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure718Current assets, Q2 FY2026, at 2026-06-30$717.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Total assets$m1,007Total assets, Q3 FY2023, at 2023-09-30$1.01bn. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-02, accession 0001439222-23-000140.Report this figure937Total assets, FY2023, at 2023-12-31$937.1m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-13, accession 0001439222-25-000009.Report this figure850Total assets, Q1 FY2024, at 2024-03-31$849.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-02, accession 0001439222-24-000069.Report this figure773Total assets, Q2 FY2024, at 2024-06-30$773.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-01, accession 0001439222-24-000121.Report this figure1,792Total assets, Q3 FY2024, at 2024-09-30$1.79bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure1,663Total assets, FY2024, at 2024-12-31$1.66bn. XBRL concept us-gaap:Assets. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure1,556Total assets, Q1 FY2025, at 2025-03-31$1.56bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure1,471Total assets, Q2 FY2025, at 2025-06-30$1.47bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-07-31, accession 0001439222-25-000089.Report this figure1,386Total assets, Q3 FY2025, at 2025-09-30$1.39bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure1,297Total assets, FY2025, at 2025-12-31$1.30bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure1,185Total assets, Q1 FY2026, at 2026-03-31$1.18bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure1,108Total assets, Q2 FY2026, at 2026-06-30$1.11bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Current liabilities$m58.4Current liabilities, Q3 FY2023, at 2023-09-30$58.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-02, accession 0001439222-23-000140.Report this figure68.0Current liabilities, FY2023, at 2023-12-31$68.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-13, accession 0001439222-25-000009.Report this figure51.7Current liabilities, Q1 FY2024, at 2024-03-31$51.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-02, accession 0001439222-24-000069.Report this figure62.6Current liabilities, Q2 FY2024, at 2024-06-30$62.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-01, accession 0001439222-24-000121.Report this figure119Current liabilities, Q3 FY2024, at 2024-09-30$119.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure81.2Current liabilities, FY2024, at 2024-12-31$81.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure52.4Current liabilities, Q1 FY2025, at 2025-03-31$52.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure70.4Current liabilities, Q2 FY2025, at 2025-06-30$70.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-07-31, accession 0001439222-25-000089.Report this figure74.8Current liabilities, Q3 FY2025, at 2025-09-30$74.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure82.2Current liabilities, FY2025, at 2025-12-31$82.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure58.8Current liabilities, Q1 FY2026, at 2026-03-31$58.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure70.2Current liabilities, Q2 FY2026, at 2026-06-30$70.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Total liabilities$m120Total liabilities, Q3 FY2023, at 2023-09-30$120.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-02, accession 0001439222-23-000140.Report this figure126Total liabilities, FY2023, at 2023-12-31$126.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-13, accession 0001439222-25-000009.Report this figure106Total liabilities, Q1 FY2024, at 2024-03-31$105.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-02, accession 0001439222-24-000069.Report this figure113Total liabilities, Q2 FY2024, at 2024-06-30$112.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-01, accession 0001439222-24-000121.Report this figure165Total liabilities, Q3 FY2024, at 2024-09-30$165.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure122Total liabilities, FY2024, at 2024-12-31$122.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure89.0Total liabilities, Q1 FY2025, at 2025-03-31$89.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure102Total liabilities, Q2 FY2025, at 2025-06-30$101.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-07-31, accession 0001439222-25-000089.Report this figure101Total liabilities, Q3 FY2025, at 2025-09-30$101.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure104Total liabilities, FY2025, at 2025-12-31$104.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure75.9Total liabilities, Q1 FY2026, at 2026-03-31$75.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure82.4Total liabilities, Q2 FY2026, at 2026-06-30$82.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Shareholders' equity$m887Shareholders' equity, Q3 FY2023, at 2023-09-30$886.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure811Shareholders' equity, FY2023, at 2023-12-31$811.0m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure744Shareholders' equity, Q1 FY2024, at 2024-03-31$743.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure661Shareholders' equity, Q2 FY2024, at 2024-06-30$660.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure1,627Shareholders' equity, Q3 FY2024, at 2024-09-30$1.63bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure1,541Shareholders' equity, FY2024, at 2024-12-31$1.54bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure1,467Shareholders' equity, Q1 FY2025, at 2025-03-31$1.47bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure1,370Shareholders' equity, Q2 FY2025, at 2025-06-30$1.37bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure1,284Shareholders' equity, Q3 FY2025, at 2025-09-30$1.28bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure1,193Shareholders' equity, FY2025, at 2025-12-31$1.19bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure1,109Shareholders' equity, Q1 FY2026, at 2026-03-31$1.11bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure1,026Shareholders' equity, Q2 FY2026, at 2026-06-30$1.03bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure

Cash flow

Operating cash flow−$57.3m, Q2 FY2026
Capital expenditure$1.2m, Q2 FY2026
Agios Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(61.6)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$61.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-10-31, accession 0001439222-24-000138. Derived: 9-month figure less the 6-month figure.Report this figure(72.5)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$72.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(99.9)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$99.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure(72.6)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$72.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-07-31, accession 0001439222-25-000089. Derived: 6-month figure less the 3-month figure.Report this figure(84.2)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$84.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0001439222-25-000116. Derived: 9-month figure less the 6-month figure.Report this figure(133)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$133.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(111)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$111.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(77.1)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$77.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0001439222-26-000118. Derived: 6-month figure less the 3-month figure.Report this figure(88.2)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$88.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0001439222-25-000116. Derived: 9-month figure less the 6-month figure.Report this figure(96.2)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$96.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(119)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$118.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(57.3)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$57.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0001439222-26-000118. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.4Capital expenditure, Q3 FY2023, three months to 2023-09-30$369.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-10-31, accession 0001439222-24-000138. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2023, three months to 2023-12-31$234.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2024, three months to 2024-03-31$141.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure0.2Capital expenditure, Q2 FY2024, three months to 2024-06-30$158.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-07-31, accession 0001439222-25-000089. Derived: 6-month figure less the 3-month figure.Report this figure0.4Capital expenditure, Q3 FY2024, three months to 2024-09-30$419.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-30, accession 0001439222-25-000116. Derived: 9-month figure less the 6-month figure.Report this figure1.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$967.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure0.8Capital expenditure, Q1 FY2025, three months to 2025-03-31$766.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure0.9Capital expenditure, Q2 FY2025, three months to 2025-06-30$875.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0001439222-26-000118. Derived: 6-month figure less the 3-month figure.Report this figure1.6Capital expenditure, Q3 FY2025, three months to 2025-09-30$1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-30, accession 0001439222-25-000116. Derived: 9-month figure less the 6-month figure.Report this figure1.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure0.8Capital expenditure, Q1 FY2026, three months to 2026-03-31$769.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure1.2Capital expenditure, Q2 FY2026, three months to 2026-06-30$1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0001439222-26-000118. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)59.49m, Q2 FY2026
Agios Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares54.8Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3054,844,579 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-02, accession 0001439222-23-000140.Report this figure55.3Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3155,265,390 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-02, accession 0001439222-24-000069.Report this figure55.6Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3055,604,330 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-01, accession 0001439222-24-000121.Report this figure55.8Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3055,803,663 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-10-31, accession 0001439222-24-000138.Report this figure56.4Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3156,383,475 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-01, accession 0001439222-25-000036.Report this figure56.8Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3056,802,546 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-07-31, accession 0001439222-25-000089.Report this figure58.4Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3058,432,796 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure57.5Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3157,459,195 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure57.9Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3057,932,576 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure58.1Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3058,139,277 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure58.8Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3158,782,241 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure59.5Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3059,488,871 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure

Shares outstanding: 59.70mShares outstanding, period not labelled, at 2026-07-2459,701,882 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure at Jul 24, 2026, from the cover of the 10-Q filed Jul 30, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. Listed shows no prices and gives no investment advice.